Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there is strong sales growth and improved cash burn, the financial health is weakened by operating losses and a net loss. The shareholder return plan is neutral, with a share issuance and reduced cash burn. The Q&A section reveals uncertainties, particularly around regulatory risks and unclear guidance on key metrics. Despite strong financial performance, the market strategy faces competition and regulatory challenges. Overall, the sentiment is neutral, with no strong catalysts for significant short-term stock price movement.
Total Revenues €49.2 million, an increase of 50.0% year-over-year from €32.8 million, driven by strong product sales.
Product Sales €48.6 million, an increase of 51.2% year-over-year, driven by strong IXIARO sales and replenishment in indirect markets.
IXIARO Sales €27.5 million, an increase of 65.5% year-over-year, driven by increased sales to the US military and travel channels.
DUKORAL Sales €12.3 million, an increase of 9.4% year-over-year, primarily due to shipments to Mayotte.
IXCHIQ Sales €3 million, compared to €200,000 in the prior year, driven by ramp-up in the US and launch in additional territories.
Gross Margin on Commercial Products 62.7%, up from 43.9% year-over-year, due to better manufacturing performance and fewer batch failures.
IXIARO Gross Margin 72.6%, up from 62% year-over-year, exceeding pre-COVID levels.
DUKORAL Gross Margin 52.2%, up from below 40% year-over-year.
Operating Loss €6 million, compared to an operating profit of €68.2 million in the prior year, due to the prior year's non-recurring revenue from the sale of a Priority Review Voucher.
Net Loss €9.2 million, compared to a profit of €58.9 million in the prior year, impacted by the previous year's one-time revenue.
Cash Position €153 million at the end of March, down from €168 million at the end of the prior fiscal year.
Cash Used in Operations €8.1 million, significantly reduced from €28.4 million in the prior year, driven by higher sales and cost control.
New IXIARO contract: A new IXIARO contract was awarded by the US Department of Defense.
IXCHIQ sales: IXCHIQ sales reached €3 million in Q1 2025, a significant increase from €200,000 in Q1 2024.
DUKORAL sales: DUKORAL sales grew by 9.4% to €12.3 million, driven by shipments to Mayotte.
Shigella vaccine candidate: Initiated Phase 2 infant study for the tetravalent Shigella vaccine candidate S4V2.
Zika vaccine candidate: Expect Phase 1 results later this year for the second-generation Zika vaccine candidate.
IXCHIQ marketing authorization: Received marketing authorization for IXCHIQ in the UK for individuals 18 years and older.
IXCHIQ label extension: Received IXCHIQ label extension in Europe for individuals 12 years and older.
IXCHIQ approval in Brazil: IXCHIQ marketing authorization in Brazil represents the first approval of the chikungunya vaccine in an endemic country.
Cash position: Cash position north of €150 million, reflecting a reduction in operating cash burn.
Gross margin improvement: Gross margin on commercial products, excluding IXCHIQ, improved to 62.7%.
Operational cash burn reduction: Reduced cash used in operations from €28.4 million to €8.1 million.
Focus on Lyme disease vaccine: Expecting first data from the Phase 3 study of the Lyme disease vaccine by the end of the year.
Post-marketing effectiveness program for IXCHIQ: Preparing for a Phase 4 program to confirm IXCHIQ's effectiveness following licensure.
Regulatory Risks: Recent changes to IXCHIQ recommendations due to reports of serious adverse events in frail elderly individuals, leading to precautionary measures by health authorities.
Supply Chain Challenges: Previous supply constraints impacted sales in the first quarter of 2024, although improvements were noted in the current quarter.
Economic Factors: Operating loss reported at €6 million, compared to a profit of €68.2 million in the prior year, primarily due to non-recurring revenue from the sale of a Priority Review Voucher.
Market Competition: The company faces competitive pressures in the vaccine market, particularly for Lyme disease and chikungunya vaccines.
Clinical Development Risks: Delays in clinical data for the Shigella vaccine program, with pilot efficacy data now expected in the first half of next year instead of the second half of this year.
IXCHIQ Contract: A new IXIARO contract awarded by the US Department of Defense and response to chikungunya outbreaks in La Réunion and Mayotte.
Regulatory Achievements: Marketing authorization for IXCHIQ in the UK and Brazil, and label extensions for adolescents in Europe.
Lyme Disease Vaccine: Ongoing Phase 3 study (VALOR) for Lyme vaccine with expected data by end of 2025.
Shigella Vaccine: Phase 2 infant study launched, with pilot efficacy data expected in the first half of 2026.
Zika Vaccine: Phase 1 results expected later in 2025 for a second-generation Zika vaccine.
Product Sales Guidance: Product sales guidance of €170 million to €180 million for fiscal year 2025.
Total Revenues Guidance: Total revenues guidance of €180 million to €190 million for fiscal year 2025.
R&D Expenses Guidance: Total R&D expenses expected to be between €90 million and €100 million.
Operational Cash Burn: On track to reduce operational cash burn by 50% on a full-year basis.
Profitability Outlook: Potential sustained profitability from 2027 based on successful Lyme disease vaccine approval.
Share Issuance: In the first quarter of 2025, Valneva issued new shares for a value of €14.2 million through their At the Market program.
Cash Position: Total cash and cash equivalents at the end of March were €153 million.
Operational Cash Burn: The company significantly reduced cash used in operations from €28.4 million to €8.1 million compared to the prior year.
Sales Guidance: Valneva reiterated its product sales guidance of €170 million to €180 million for the fiscal year 2025.
Profitability Outlook: The company sees a path to potential sustained profitability from 2027 based on successful Lyme disease vaccine approval and commercialization.
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.
The earnings call reveals mixed signals. While there are strong regulatory achievements and promising vaccine developments, the financial performance shows significant operating losses and reduced cash position. Guidance remains steady, but the lack of additional revenue recognition and vague responses in the Q&A highlight uncertainties. The operational cash burn reduction is positive, but overall, the sentiment is balanced by both positive and negative factors, leading to a neutral outlook.
The earnings call presents a mixed picture. While there is strong sales growth and improved cash burn, the financial health is weakened by operating losses and a net loss. The shareholder return plan is neutral, with a share issuance and reduced cash burn. The Q&A section reveals uncertainties, particularly around regulatory risks and unclear guidance on key metrics. Despite strong financial performance, the market strategy faces competition and regulatory challenges. Overall, the sentiment is neutral, with no strong catalysts for significant short-term stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
